|Articles|September 7, 2021
Pharmacy Clinical Pearl of the Day: Psoriasis
Author(s)Saro Arakelians, PharmD
Psoriasis is a common, long-term chronic disease with no cure that goes through cycles, flaring for a few weeks or months, then going into remission.
Advertisement
Clinical Pearl of the Day: Psoriasis
Psoriasis is a skin disease that causes red, itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp.
Explanation:
- Psoriasis is a common, long-term chronic disease with no cure.
- It goes through cycles, flaring for a few weeks or months, then subsiding for a while or going into remission.
- Symptoms include: Red patches of skin covered with thick, silvery scales, small scaling spots (commonly seen in children), dry and cracked skin that may bleed or itch, burning or soreness, thickened and pitted or ridged nails, swollen and stiff joints.
- Types of psoriasis include plaque psoriasis, nail psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis.
- Treatments include: corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, salicylic acid, coal tar, Goeckerman therapy, and anthralin.
Reference:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5